600666.SH
奥瑞德
SSE · Healthcare · Drug Manufacturers - General · CN
CNY 3.38
−2.87%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 487.4M | 465.1M | 366.0M | 327.9M | 531.3M |
| Cost of Revenue | 413.7M | 398.6M | 316.2M | 350.9M | 494.9M |
| Gross Profit | 73.8M | 66.5M | 49.8M | (23.0M) | 36.4M |
| Operating Expenses | |||||
| R&D Expense | 21.3M | 24.5M | 25.9M | 32.4M | 90.1M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 72.3M | 77.6M | 92.5M | 98.5M | 111.8M |
| Selling & Marketing Expense | 4.1M | 4.3M | 4.5M | 3.7M | 11.1M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 112.4M | 115.4M | 129.2M | 130.4M | 348.3M |
| Cost and Expenses | 526.1M | 513.9M | 445.3M | 481.3M | 843.2M |
| Operating Income (EBIT) | 174.0M | 174.3M | (138.2M) | (505.3M) | 630.5M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 168.9M | 169.1M | (122.0M) | (610.0M) | 59.0M |
| Income Tax Expense | 36.5M | 36.4M | 52.3M | 72.5M | (551.1K) |
| Bottom Line | |||||
| Net Income | 140.0M | 141.4M | (171.4M) | (675.3M) | 60.5M |
| Earnings from Cont. Ops | 148.0M | 150.5M | (168.9M) | (682.5M) | 59.5M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 140.0M | 141.4M | (171.4M) | (675.3M) | 60.5M |
| Per Share | |||||
| Basic EPS | CN¥0.05 | CN¥0.05 | (CN¥0.06) | (CN¥0.24) | CN¥0.02 |
| Diluted EPS | CN¥0.05 | CN¥0.05 | (CN¥0.06) | (CN¥0.24) | CN¥0.02 |
| Revenue Per Share | CN¥0.18 | CN¥0.17 | CN¥0.13 | CN¥0.12 | — |
| Shares | |||||
| Basic Shares Outstanding | 2.8B | 2.7B | 2.8B | 2.8B | — |
| Diluted Shares Outstanding | 2.8B | 2.7B | 2.8B | 2.8B | — |
| Profitability Metrics | |||||
| EBITDA | — | 307.7M | 13.0M | (410.8M) | 770.0M |
| D&A | — | 133.4M | 151.2M | 94.5M | 139.5M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026